Brief: Design Therapeutics Completes Dosing In First Patient Cohort Of Phase 1 Trial Of DT-216 GeneTAC™ Molecule For The Treatment Of Friedreich Ataxia
30/03/2022 12:07
March 30 (Reuters) - Design Therapeutics Inc DSGN.O :
* DESIGN THERAPEUTICS COMPLETES DOSING IN FIRST PATIENT
COHORT OF
PHASE 1 TRIAL OF DT-216 GENETAC™ MOLECULE FOR THE TREATMENT OF
FRIEDREICH ATAXIA
Source text for Eikon: ID:nGNX67GH0F
Further company coverage: DSGN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Design Therapeutics
See all newsDesign Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Design Therapeutics Q2 net loss narrower than expected
Brief: Design Therapeutics Q2 Basic EPS USD -0.32
Design Therapeutics Inc expected to post a loss of 34 cents a share - Earnings Preview
Brief: Design Therapeutics Announces Initiation Of Patient Dosing In Phase 1 Multiple Ascending Dose Trial Of Dt-818 For Myotonic Dystrophy Type-1